NVO

Novo Nordisk (NVO) is the lead sponsor of 91 active clinical trials listed on ClinicalTrials.gov^[5], including 32 Phase 3^[1], 9 Phase 2^[2], 17 Phase 1^[3], 3 Phase 4^[4].

Trial NCT05330325^[6] evaluates Somapacitan in SGA, Turner Syndrome, Noonan Syndrome, ISS with a target enrollment of 412 participants. Trial NCT05567796^[7] evaluates Cagrilintide in Obesity with a target enrollment of 3400 participants. Trial NCT03811561^[8] evaluates Semaglutide in Diabetes Mellitus, Type 2 with a target enrollment of 1500 participants.